Omeros swings to Q4 profit on sale of zaltenibart

Overview

• Biotechnology company reported Q4 net income of $86.5 mln, up from a year-ago loss

• Q4 results include $237.6 mln gain from zaltenibart sale to Novo Nordisk

Outlook

• Company expects EMA decision on YARTEMLEA marketing authorization in mid-2026

• Omeros targets positive cash flow in 2027

Result Drivers

• ZALTENIBART SALE - Q4 results driven by $237.6 mln gain from sale of zaltenibart to Novo Nordisk

• OPERATING EXPENSES - Lower operating expenses due to reduced manufacturing and clinical trial costs and spending cuts ahead of YARTEMLEA launch

Company press release: ID:nBwb2bs4la

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Omeros Corp is $40.00, about 307.7% above its March 30 closing price of $9.81

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.